ZETA GLOBAL HOLDINGS CORP. (ZETA): what the price assumes
In the published model solve dated 2026-Q2, anchored at $22.07, ZETA GLOBAL HOLDINGS CORP. (ZETA) is priced for today's economics sustained for ~6.9 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.
Generated: 2026-08-01 · Exported: 2026-08-03 · Source: https://boothcheck.com/report/ZETA
Headline
| Field | Value |
|---|---|
| Ticker | ZETA |
| Company | ZETA GLOBAL HOLDINGS CORP. |
| Current price | $22.07/sh |
| Composition | US 96% / International 4% |
What The Price Assumes (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | revenue-multiple |
| EV / sales paid | 3.6x |
| Steady-state operating margin assumed | 24.3% |
| Must persist for | 6.9y |
Solve inputs: computed at a 13.3% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~1.7 years.
Reconcile: at the x-ray's 9.3% required return this reads ~7.3%/yr; the models below use their own rates.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | -0.48σ |
| sustained it ~6.9 years at this level | 23% |
| implied end-window share | 0% |
Valuation X-Ray
The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 6.31x | 2 | expensive |
| Earnings | 2.36x | 1 | expensive |
| Relative | 0.46x | 3 | justifies |
| Growth | 0.63x | 4 | justifies |
Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.9%); the inversion above states its own rate.
Per-Model Detail (n=10)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $38.65 | 0.57x | yes | FCF base $0.2B, growth 25% (input: historical growth), terminal g 4.0%, WACC 8.9%, 7yr projection |
| DCF Exit Multiple | Growth | $29.25 | 0.75x | yes | Exit EV/EBITDA: 61.5x / 64.5x / 67.5x (bear / base = today's held flat / bull), 7yr |
| Relative Valuation | Relative | $48.18 | 0.46x | yes | P/S fallback (negative EPS): Sector P/S 8.0x × TTM revenue — excluded from consensus |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $3.69 | 5.98x | yes | Book value floor: BV/sh $3.69, ROE negative |
| Two-Stage Excess Return | Asset | $3.32 | 6.65x | yes | Book value with convergence: BV/sh $3.69, ROE converges to ke |
| Discounted Future Market Cap | Growth | $32.02 | 0.69x | yes | Rev $1.4B, growth 30% (input: historical growth; tapered), Terminal P/S: 2.9x / 3.7x / 4.4x (bear / base = today's held flat / bull, cap 12x) |
| Peter Lynch Fair Value | Relative | $0.00 | — | no | Negative/zero EPS — earnings-based value floored at $0 |
| Margin Trajectory | Growth | $54.65 | 0.40x | yes | Margin ramp: -2% → 22% over 7yr, rev growth 30% (input: historical growth; tapered) |
| Earnings Power Value | Earnings | — | — | no | — |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | $8.73 | 2.53x | yes | EBITDA $0.08B × sector EV/EBITDA 25.0x |
| FCF Yield | Earnings | $9.35 | 2.36x | yes | FCF $199.7M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $0.79 | 27.93x | yes | SBC-adj FCF $0.01B (FCF $0.20B − SBC $0.19B) capitalized at Kₑ (excluded from median) |
| Ben Graham Formula | Earnings | — | — | no | — |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $48.18 | 0.46x | yes | Revenue $1.44B × sector P/S 8.0x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | — | — | no | — |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net cash | $91.5m |
| Net debt / NOPAT (after-tax) | -43.77x (net cash) |
| Net debt / operating income (pre-tax) | -34.58x (net cash) |
| Interest coverage | 3.3x |
| Share count CAGR (dilution) | 15.5% |
| Burning cash | no |
Bullet Takeaways
- Zeta Global runs an AI-driven marketing platform built on a large proprietary data set, and it monetizes by deepening its biggest accounts, with scaled-customer average revenue per user rising 13% to about $2.1 million in 2025.
- The defining risk is dilution: the company runs a real GAAP net loss, $31.5 million in 2025, that includes about $178 million of stock-based compensation, and the share count is growing at roughly 15% a year.
- What to watch is the growth mix: revenue rose 30% to $1.305 billion in 2025 and 2026 guidance implies 34% to 35% growth, but excluding political and the Marigold acquisition the organic rate is closer to 20% to 21%.
Bull Case
Marketing technology is a sector where the winner is whoever has the best data and can act on it fastest, and that is the lens through which Zeta's case is strongest. The platform combines a proprietary data set with AI to help brands target and message customers, and the company describes its edge as building "new products on a timely and cost-effective basis, meeting evolving customer needs, providing best-in-class data security, extending our core technology into new applications." In martech, scale begets scale: more customers and more data improve the models, which improves the targeting, which attracts more customers. Zeta is demonstrating that flywheel through its existing base rather than just new logos, with scaled-customer average revenue per user up 13% to about $2.1 million in 2025 and super-scaled accounts reaching about $6.16 million. Land-and-expand at that pace is the healthiest growth a software company can have, because it monetizes relationships it already paid to win.
The top-line momentum is genuinely strong. Full-year 2025 revenue grew 30% to $1.305 billion, the fourth quarter rose 25% to $395 million, and the company has now strung together eighteen consecutive beat-and-raise quarters. A consistent beat-and-raise record signals management is forecasting conservatively and executing ahead of its own guidance, which is the opposite of the over-promising that sinks many growth-software stories. The Marigold acquisition adds enterprise relationships and cross-sell, and 2026 guidance for 34% to 35% revenue growth reflects both the acquisition and continued organic strength in the low-twenties.
The inflection toward GAAP profitability is the part the market is starting to credit. Zeta posted positive GAAP net income of $6.5 million in the fourth quarter, a 1.7% margin, and guided to positive GAAP net income for full-year 2026. For a growth-software company, crossing into GAAP profitability while still growing north of 30% is the signal that the unit economics work and the model can self-fund. The valuation lenses reflect a name in transition: the relative-multiple and growth-DCF methods support the price, and analysts carry a strong-buy consensus with targets well above the current level.
Bear Case
The cleanest bear observation is that Zeta's reported profitability and its actual profitability are different numbers, and the gap is paid by shareholders. The company reported positive GAAP net income in the fourth quarter, but the full-year 2025 GAAP result was a net loss of $31.5 million, which included about $178 million of stock-based compensation. Stock-based compensation is a real cost, it is the equity handed to employees instead of cash, and at $178 million against a business this size it is the difference between the GAAP loss and the adjusted profit the company prefers to highlight. The consequence shows up directly in the share count, which is growing at roughly 15% a year. A company diluting holders at that pace has to grow per-share value much faster than total value just to stand still, and the buyer is funding the growth partly through their own dilution.
The growth itself deserves a second look. Headline 2026 guidance is for 34% to 35% revenue growth, but excluding political-candidate revenue and the Marigold acquisition, the underlying organic rate is 20% to 21%. Political revenue is episodic, tied to election cycles, and acquisition revenue is bought, not earned, so the durable organic engine is meaningfully slower than the headline suggests. For a stock whose price embeds years of high growth, the distinction between 35% reported and 20% organic is the whole valuation question, because the organic rate is what compounds after the election fades and the acquisition laps.
The structural risk is regulatory, and it sits at the heart of the business model. Zeta's value depends on collecting and acting on consumer data, and the 10-K is candid that regulation governs "the ways in which we may use or disclose data," that frameworks like "the GDPR permit data protection authorities to impose penalties for violations," and that the company expects "existing legal complexity and uncertainty regarding international data transfers to continue." Tightening privacy law, restrictions on data transfers, or the broader deprecation of tracking identifiers could erode the proprietary data advantage the entire thesis rests on. The valuation amplifies the stakes: at about 3.4 times revenue the price implies the business eventually earns a roughly 24% operating margin and grows at its self-funding ceiling for about six years, a path only about 28% of comparable fast-growers have sustained, and the asset and earnings-power lenses already call the price expensive. If the organic growth normalizes or a privacy shock hits, there is little static value beneath the price to catch it.
Valuation
Trailing operating profit sits below the steady-state level the price assumes, so the stock is best read against its sales rather than its earnings. At about 3.4 times revenue, the price implies the business eventually earns an operating margin near 24% and grows revenue at its self-funding ceiling for roughly six years. That is a demanding combination: the company must both scale its margin from today's near-breakeven GAAP level and sustain rapid growth, and only about 28% of comparable fast-growers have held this pace for six years. The read is labeled elevated, above what the fundamentals comfortably support.
The valuation families split as they do for a high-growth, not-yet-GAAP-profitable software name. The relative-multiple and growth-DCF lenses support the price, while the asset-based and earnings-power lenses call it expensive. The reconciliation is the margin-expansion story: the static methods value the thin current earnings, while the forward lenses credit the operating leverage the platform should produce as it scales. The price is paying for that leverage to materialize, which means the durability of the organic growth and the path to real GAAP margins, not just adjusted ones, are what the valuation rests on.
Solvency is adequate but not a fortress. The company holds modest net cash, about $91 million, against roughly $197 million of gross debt, and interest coverage is thin given the near-breakeven operating income. The more important balance-sheet fact is the equity dilution, not the debt: stock-based compensation around $178 million a year and a 15% annual increase in shares mean the per-share trajectory lags the total-business trajectory. The downside is not insolvency; it is a re-rating if organic growth slows toward the low twenties, if the margin expansion proves slower than the price assumes, or if data regulation pressures the model, against a price that only the growth-crediting lenses currently justify.
Catalysts
The fourth-quarter and full-year 2025 results, reported in early 2026, extended a long run of outperformance. Fourth-quarter revenue rose 25% to $395 million, full-year revenue grew 30% to $1.305 billion, and the company logged its eighteenth consecutive beat-and-raise quarter, while posting positive GAAP net income of $6.5 million in the quarter against a full-year GAAP net loss of $31.5 million driven by stock-based compensation. The scaled-customer monetization continued, with average revenue per user climbing on both scaled and super-scaled accounts.
The 2026 guidance and the Marigold acquisition are the forward catalysts. Management raised full-year 2026 revenue guidance to $1.749 to $1.762 billion, 34% to 35% growth, with organic growth excluding political and Marigold at 20% to 21%, and guided to adjusted EBITDA margins above 22% and positive full-year GAAP net income. The integration of Marigold and the cross-sell into its enterprise base is the lever to watch for whether the acquisition adds durable growth or just one-time scale.
Sentiment is strongly positive. Analysts carry a strong-buy consensus with an average price target around $28, and Bank of America raised its target to $28 with a buy rating. The events most likely to move the thesis from here are the organic-growth prints once political revenue fades, the pace of GAAP margin improvement against the heavy stock-based compensation, the integration of Marigold, and any change in the data-privacy regulatory landscape that bears on the platform's data advantage.
Peer Cohorts (Per Segment, With Filing Citations)
Zeta Global (consolidated) (reported)
- KVYO (Klaviyo, Inc.)
- (no filing in the citation store)
- SEMR (Semrush Holdings, Inc.)
- (no filing in the citation store)
- TTD (TRADE DESK, INC.)
- (no filing in the citation store)
- RAMP (LiveRamp Holdings, Inc.)
- (no filing in the citation store)
- DV (DoubleVerify Holdings, Inc.)
- (no filing in the citation store)
- TWLO (TWILIO INC.)
- (no filing in the citation store)
- FRSH (Freshworks Inc.)
- (no filing in the citation store)
- PLTR (Palantir Technologies Inc.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Zeta Global Q4 2025 results and 2026 guidance · Zeta Global FY2025 10-K · Zeta Global Q4 2025 results, February 2026 · Zeta Global Q4 2025 results and guidance · analyst notes via stockanalysis.com and BofA, 2026 · Zeta Global Q4 2025 results · Zeta Global 2026 guidance